Novartis Hopes To Broaden SMA Patient Pool After Intrathecal Zolgensma Success

The Swiss giant’s blockbuster gene therapy is currently only administered intravenously into patients with spinal muscular atrophy under two years of age. Its intrathecal candidate, called OAV-101, has just passed a Phase III test which could expand its use in children and young adults.